|
|
|
|
|
|
|
|
|
Webinar: Whose table is it? Patient organizations becoming drug development drivers
|
Patient organizations are moving beyond advisory roles to become active drivers of rare disease drug development. Join Craig Lipset and Dr. Derk Arts to explore how patient-led registries, natural-history data, real-world evidence, drug repurposing, and master protocols can help derisk clinical development. Discover what this emerging model looks like today, where its limits lie, and how clinical-development leaders can learn from early pioneers. Click here to learn more.
|
|
|
|
|
|
Video | TruTechnologies
|
Biomarkers and other specialty lab samples are among the most fragile parts of clinical trial execution, but what makes them so vulnerable to mishandling, and what are the effects?
|
|
|
|
|
|
Webinar | CRIO
|
Join the Co-CEO of CRIO, as he explores research site challenges and how site-based technologies can reduce administrative burdens, enhance efficiency, and eliminate redundant one-time-use technologies.
|
|
|
|
|
|
Video | IQVIA Technologies
|
In this presentation, you’ll get recommendations to help you stay inspection-ready and learn about the importance of clear roles, audit trails, data integrity, and training.
|
|
|
|
|
|
Video | Scout
|
Clinical trials rely on smooth coordination between participants, sites, and sponsors. Payment, travel, and logistical support help reduce barriers, simplify administration, and keep studies moving forward.
|
|
|
|
|
|
Video | Worldwide Flex
|
Why is functional outsourcing important in today's clinical development environment, and where can you find scalable support that will flex with your changing needs?
|
|
|
|
|
|
Video | Clinical Leader
|
In March 2026, consultants Brian Whitlock and Samir Shah presented data at the TD Cowen Healthcare Conference quantifying the impact of AI-enabled trial delivery on a hypothetical Phase III study. On 4/1/26, Clinical Leader hosted an exclusive webinar summarizing the data Whitlock and Shah presented. The webinar also included Mark Travers and Sheryl Jacobs, two other pharma executive consultants, who gave their views on the data, along with practical maturation timing and barriers in pharma clinical development.
|
|
|
|
|
|
Video | Avance Clinical
|
This presentation outlines the key success factors driving high-impact oncology drug development, with a focus on translating innovative science into clinically and commercially meaningful outcomes.
|
|
|
| Connect With Clinical Leader: |
|
|
|
|
